A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

Site US10013 Advanced Urology Centers of New York, Plainview

Site US10020 Upstate Clinical Research Associates LLC, Williamsville

Site US10014 Mid Atlantic Clinical Research, Greenbelt

Site US10032 Clinical Research and Consulting Center, LLC, Fairfax

Site US10035 Millennium Clinical Research Center, Arlington

Site US10034 Health Research of Hampton Roads Inc, Newport News

Site US10033 Eastern Research, Hialeah

Site US10023 Advanced Clinical Research of Miami, Miami

Site US10022 Palm Beach Research Center, West Palm Beach

Site US10007 Pinellas Urology, Inc, St. Petersburg

Site US10002 Urology Centers of Alabama, Homewood

Site US10017 The Jackson Clinic, Jackson

Site US10008 The Iowa Clinic PC, Urology, West Des Moines

Site US10057 Practice Research Organization, Dallas

Site US10001 Urological Associates of Southern Arizona, Tucson

Site US10010 Skyline Urology, Sherman Oaks

Site US10003 Genesis Research, San Diego

Site US10004 Alaska Clinical Research Center, LLC, Anchorage

Site US10028 Clinical Research Consulting, Milford

Site US10024 Coastal Connecticut Research, LLC, New London

Site US10005 Boston Clinical Trials, Boston

Site US10021 AccuMed Research Associates, Garden City

Site CA15012 Glover Medical Clinic, Langley

Site CA15008 Silverado Research, Victoria

Site CA15003 The Male/Female Health & Research Centre, Barrie

Site CA15001 Jonathan Giddens Medicine Professional Corporation, Brampton

Site CA15011 Scisco Clinical Research, Cornwall

Site CA15002 RechercheGCP Research, Granby

Site CA15007 RechercheGCP Research, Montreal

Site CA15005 CHUS - Hopital Fleurimont, Sherbrooke